Caribou Biosciences

Caribou Biosciences

Caribou Biosciences

Pioneering the revolutionary field of CRISPR-Cas genome editing to advance therapeutics, agricultural biotech, biological research, and industrial biotech.
Suggest edits
Type
B2c
Founded
2011
Raised
$32.9M
Follow us
Also headquartered in Berkeley
Companies in the same industry
Alexa global traffic share
Twitter followers
Terms of Service Privacy Policy Cookie Statement
Built with ❤︎ by Datalicious ©2022
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 3

Add info
Latest funding Show all
$30,000,000
Venture capital (Series B) - 2016
Heritage Group Novartis F-Prime Capital Partners +5
Undisclosed amount
Venture capital - 2015
Novartis
Team Size
10+
Employees
I work here
Location
Berkeley ,  United States
Headquarters
Explore Berkeley
Pulse 2.0

Caribou Biosciences (CRBU) Stock: $28 Price Target From H.C. Wainwright

Caribou Biosciences
Caribou Biosciences
MedCity News

CRISPR biotech Caribou Biosciences’ IPO reels in $304M for next-gen cell therapy

Caribou Biosciences
Caribou Biosciences
$30,000,000 Venture capital (Series B)
FinSMEs

Caribou Biosciences Completes $30M Series B Funding

Funding Science
Caribou Biosciences
Caribou Biosciences
Venture capital
GEN

GEN | News Highlights:Novartis Launches CRISPR Collaborations with Intellia, Caribou